Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Ovarian Neoplasms 7Neoplasms 6Fallopian Tube Neoplasms 6Neoplasm Metastasis 5Carcinoma 4Colorectal Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Sarcoma 2Hemangiosarcoma 2Glioblastoma 2Gastrointestinal Neoplasms 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Oligodendroglioma 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Kidney Diseases 1

Interventions

Cytarabine 85fludarabine phosphate 84Peripheral Blood Stem Cell Transplantation 75Cyclophosphamide 69Busulfan 62Mycophenolic Acid 50Cyclosporine 48Tacrolimus 47Etoposide 43Whole-Body Irradiation 41Antilymphocyte Serum 40Methotrexate 39Filgrastim 39Radiotherapy 29Melphalan 24Mitoxantrone 23Daunorubicin 23Idarubicin 21Cord Blood Stem Cell Transplantation 18Methylprednisolone 17Flow Cytometry 17sargramostim 15Granulocyte Colony-Stimulating Factor 15Clofarabine 15Transplantation 14Decitabine 14aldesleukin 12Gemtuzumab 12Thiotepa 11Bortezomib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Congenital Abnormalities × trebananib × Clear all
NCT01555268 2022-09-13

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Completed
24 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡